Grand Pharmaceutical Group Ltd
HKEX:512
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.28
5.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Grand Pharmaceutical Group Ltd
Accounts Payable
Grand Pharmaceutical Group Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Accounts Payable
HK$3.5B
|
CAGR 3-Years
63%
|
CAGR 5-Years
38%
|
CAGR 10-Years
20%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Accounts Payable
HK$450.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
21%
|
CAGR 10-Years
1%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Accounts Payable
¥5.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Accounts Payable
¥2.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
18%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Accounts Payable
HK$141.9B
|
CAGR 3-Years
41%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Accounts Payable
$43.4m
|
CAGR 3-Years
15%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The firm is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
See Also
What is Grand Pharmaceutical Group Ltd's Accounts Payable?
Accounts Payable
3.5B
HKD
Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Accounts Payable amounts to 3.5B HKD.
What is Grand Pharmaceutical Group Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
20%
Over the last year, the Accounts Payable growth was 240%. The average annual Accounts Payable growth rates for Grand Pharmaceutical Group Ltd have been 63% over the past three years , 38% over the past five years , and 20% over the past ten years .
You don't have any saved screeners yet
